Gilead Sciences, Inc. reported a 13% increase in third quarter revenue to $7.4bn on 28 October but the growth was driven almost entirely by Veklury (remdesivir) for which sales more than doubled from $829m in Q2 to $1.9bn in Q3 as COVID-19 hospitalizations surged due to the Delta variant of the novel coronavirus. Without Veklury, however, sales fell 3% to $5.4bn despite a 20% spike in sales to $2.3bn for Gilead’s newest HIV blockbuster Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
Gilead executives noted during a same-day earnings conference call that they remain confident in the company’s growth prospects despite ongoing...








